M D Sørensen1,2, R H Dahlrot3, H B Boldt1, S Hansen2,3, B W Kristensen1,2. 1. Department of Pathology, Odense University Hospital, Odense, Denmark. 2. Department of Clinical Research, University of Southern Denmark, Odense, Denmark. 3. Department of Oncology, Odense University Hospital, Odense, Denmark.
Abstract
AIMS: Glioblastomas are highly aggressive and treatment resistant. Increasing evidence suggests that tumour-associated macrophages/microglia (TAMs) facilitate tumour progression by acquiring a M2-like phenotype. Our objective was to investigate the prognostic value of TAMs in gliomas using automated quantitative double immunofluorescence. METHODS: Samples from 240 patients with primary glioma were stained with antibodies against ionized calcium-binding adaptor molecule-1 (IBA-1) and cluster of differentiation 204 (CD204) to detect TAMs and M2-like TAMs. The expression levels were quantified by software-based classifiers. The associations between TAMs, gemistocytic cells and glioblastoma subtype were examined with immuno- and haematoxylin-eosin stainings. Three tissue arrays containing glioblastoma specimens were included to study IBA-1/CD204 levels in central tumour and tumour periphery and to characterize CD204+ cells. RESULTS: Our data revealed that the amount of especially CD204+ TAMs increases with malignancy grade. In grade III-IV, high CD204 expression was associated with shorter survival, while high IBA-1 intensity correlated with a longer survival. In grade IV, CD204 showed independent prognostic value when adjusting for clinical data and the methylation status of O6-methylguanine-DNA methyltransferase. Our findings were confirmed in two bioinformatics databases. TAMs were more abundant in central tumour tissue, mesenchymal glioblastomas and gliomas with many gemistocytic cells. CD204+ TAMs co-expressed proteins related to tumour aggressiveness including matrix metallopeptidase-14 and hypoxia-inducible factor-1α. CONCLUSIONS: This is the first study to use automated quantitative immunofluorescence to determine the prognostic impact of TAMs. Our results suggest that M2-like TAMs hold an unfavourable prognostic value in high-grade gliomas and may contribute to a pro-tumourigenic microenvironment.
AIMS: Glioblastomas are highly aggressive and treatment resistant. Increasing evidence suggests that tumour-associated macrophages/microglia (TAMs) facilitate tumour progression by acquiring a M2-like phenotype. Our objective was to investigate the prognostic value of TAMs in gliomas using automated quantitative double immunofluorescence. METHODS: Samples from 240 patients with primary glioma were stained with antibodies against ionizedcalcium-binding adaptor molecule-1 (IBA-1) and cluster of differentiation 204 (CD204) to detect TAMs and M2-like TAMs. The expression levels were quantified by software-based classifiers. The associations between TAMs, gemistocytic cells and glioblastoma subtype were examined with immuno- and haematoxylin-eosin stainings. Three tissue arrays containing glioblastoma specimens were included to study IBA-1/CD204 levels in central tumour and tumour periphery and to characterize CD204+ cells. RESULTS: Our data revealed that the amount of especially CD204+ TAMs increases with malignancy grade. In grade III-IV, high CD204 expression was associated with shorter survival, while high IBA-1 intensity correlated with a longer survival. In grade IV, CD204 showed independent prognostic value when adjusting for clinical data and the methylation status of O6-methylguanine-DNA methyltransferase. Our findings were confirmed in two bioinformatics databases. TAMs were more abundant in central tumour tissue, mesenchymal glioblastomas and gliomas with many gemistocytic cells. CD204+ TAMs co-expressed proteins related to tumour aggressiveness including matrix metallopeptidase-14 and hypoxia-inducible factor-1α. CONCLUSIONS: This is the first study to use automated quantitative immunofluorescence to determine the prognostic impact of TAMs. Our results suggest that M2-like TAMs hold an unfavourable prognostic value in high-grade gliomas and may contribute to a pro-tumourigenic microenvironment.
Authors: Jiping Wang; Jianmei W Leavenworth; Anita B Hjelmeland; Reed Smith; Neha Patel; Ben Borg; Ying Si; Peter H King Journal: Glia Date: 2019-08-10 Impact factor: 7.452
Authors: Shubhanchi Nigam; Lauren McCarl; Rajeev Kumar; Robert S Edinger; Brenda F Kurland; Carolyn J Anderson; Ashok Panigrahy; Gary Kohanbash; W Barry Edwards Journal: Mol Imaging Biol Date: 2020-06 Impact factor: 3.488
Authors: Soumya M Turaga; Daniel J Silver; Defne Bayik; Evi Paouri; Sen Peng; Adam Lauko; Tyler J Alban; Nozha Borjini; Sarah Stanko; Ulhas P Naik; Ruth A Keri; James R Connor; Jill S Barnholtz-Sloan; Joshua B Rubin; Michael Berens; Dimitrios Davalos; Justin D Lathia Journal: Neuro Oncol Date: 2020-11-26 Impact factor: 12.300
Authors: Ali Jalali; Kwanha Yu; Vivek Beechar; Navish A Bosquez Huerta; Anthony Grichuk; Deepika Mehra; Brittney Lozzi; Kathleen Kong; Kenneth L Scott; Ganesh Rao; Matthew N Bainbridge; Melissa L Bondy; Benjamin Deneen Journal: Cancer Res Date: 2021-03-29 Impact factor: 12.701
Authors: Michael D Caponegro; Ki Oh; Miguel M Madeira; Daniel Radin; Nicholas Sterge; Maryam Tayyab; Richard A Moffitt; Stella E Tsirka Journal: Glia Date: 2021-03-11 Impact factor: 7.452